Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:23:21 EDT Tue 07 May 2024
Enter Symbol
or Name
USA
CA



News for U:VERU from 2023-05-08 to 2024-05-07 - 28 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-02 08:30U:VERUNews ReleaseVeru to Present at the GLP-1 Based Therapeutics Summit
2024-05-01 08:31U:VERUNews ReleaseVeru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024
2024-04-30 08:30U:VERUNews ReleaseVeru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
2024-04-25 08:30U:VERUNews ReleaseVeru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
2024-04-01 16:05U:VERUNews ReleaseVeru Announces Date of 2024 Annual Meeting of Shareholders
2024-03-22 16:05U:VERUNews ReleaseVeru Reschedules Annual Meeting of Shareholders
2024-03-12 08:00U:VERUNews ReleaseVeru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
2024-02-27 19:15U:VERUNews ReleaseVeru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
2024-02-20 08:30U:VERUNews ReleaseVeru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
2024-02-08 06:30U:VERUNews ReleaseVeru Reports Fiscal 2024 First Quarter Financial Highlights
2024-02-06 08:30U:VERUNews ReleaseVeru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs
2024-01-31 08:30U:VERUNews ReleaseVeru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2024-01-25 08:30U:VERUNews ReleaseVeru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024
2024-01-08 08:30U:VERUNews ReleaseVeru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss
2023-12-19 08:30U:VERUNews ReleaseVeru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs
2023-12-14 09:00U:VERUNews ReleaseVeru Announces Pricing of Public Offering of Common Stock
2023-12-13 16:01U:VERUNews ReleaseVeru Announces Proposed Public Offering of Common Stock
2023-10-04 08:30U:VERUNews ReleaseVeru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic ‚ ®, Wegovy ‚ ®, or Mounjaro ‚ ®, to Optimize Weight Loss by Preventing Muscle Wasting and Further
2023-09-26 08:30U:VERUNews ReleaseVeru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)
2023-09-20 08:30U:VERUNews ReleaseVeru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023
2023-09-11 07:00U:VERUNews ReleaseVeru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer
2023-08-30 08:30U:VERUNews ReleaseVeru to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th, 2023
2023-08-10 06:30U:VERUNews ReleaseVeru Reports Fiscal 2023 Third Quarter Financial Results
2023-08-03 08:30U:VERUNews ReleaseVeru to Report Fiscal 2023 Third Quarter Financial Results on August 10, 2023
2023-06-21 08:30U:VERUNews ReleaseVeru Inc. ¢ € ™s Oncology Drug Research Program Partner, The University of Tennessee Health Science Center, Awarded Two New Federal Grants
2023-06-01 08:30U:VERUNews ReleaseVeru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory Board
2023-05-24 08:30U:VERUNews ReleaseVeru to Present at the Jefferies Healthcare Conference
2023-05-11 06:30U:VERUNews ReleaseVeru Reports Fiscal 2023 Second Quarter Financial Results